SCHEMBL370871

SCHEMBL370871

CCC(C(=O)O)C(=O)c1cn(Cc2ccc(OC)cc2)nc1C(O)CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 1/20 0.42
KMT2A Q03164 4/20 0.41
CACNA1G O43497 3/20 0.39
CACNA1H O95180 3/20 0.39
CACNA1I Q9P0X4 3/20 0.39
MEN1 O00255 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
AADAT Q8N5Z0 1/20 0.38
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC1 Q13547 1/20 0.36
ADORA3 P0DMS8 2/20 0.36
CHRM1 P11229 2/20 0.36
SNCA P37840 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12482396 0.90 KMT2A (0.41) LDHAKMT2ACACNA1GCACNA1HCACNA1I
SCHEMBL369329 0.86 KMT2A (0.42) LDHAKMT2ACACNA1GCACNA1HCACNA1I
SCHEMBL369532 0.84 KMT2A (0.37) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL369533 0.83 CACNA1G (0.39) LDHAKMT2ACACNA1GCACNA1HCACNA1I
SCHEMBL368607 0.82 CACNA1G (0.41) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL370870 0.80 CACNA1G (0.40) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL370457 0.72 KLKB1 (0.48) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL6837432 0.72 KMT2A (0.41) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL370507 0.72 KMT2A (0.53) KMT2ACACNA1GCACNA1HCACNA1IMEN1
SCHEMBL369360 0.72 MAPT (0.47) KMT2ACACNA1GCACNA1HCACNA1IMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 LDHA 2670/4885KMT2A 1638/4885CACNA1G 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.